Answers are grounded in this paper and cite their sources.
Financial ties to industry were common and undisclosed, and scientific evidence, including systematic reviews and meta-analyses, were rarely cited. To ensure regulatory frameworks best serve patient interests, the FDA should mandate disclosure of potential conflicts of interest (including financial ties) in comments, encourage the use of scientific evidence, and encourage engagement from non-conflicted parties.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: